CN113453671A - 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法 - Google Patents

用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法 Download PDF

Info

Publication number
CN113453671A
CN113453671A CN201980092575.1A CN201980092575A CN113453671A CN 113453671 A CN113453671 A CN 113453671A CN 201980092575 A CN201980092575 A CN 201980092575A CN 113453671 A CN113453671 A CN 113453671A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
inhibitor
cancer
acceptable salt
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092575.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡波尼格罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113453671A publication Critical patent/CN113453671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980092575.1A 2018-12-20 2019-12-18 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法 Pending CN113453671A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782767P 2018-12-20 2018-12-20
US62/782,767 2018-12-20
US201962793128P 2019-01-16 2019-01-16
US62/793,128 2019-01-16
PCT/IB2019/060987 WO2020128878A1 (fr) 2018-12-20 2019-12-18 Polythérapie avec un inhibiteur de raf et un inhibiteur de cdk4/6 pour une utilisation dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CN113453671A true CN113453671A (zh) 2021-09-28

Family

ID=69165429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092575.1A Pending CN113453671A (zh) 2018-12-20 2019-12-18 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法

Country Status (12)

Country Link
EP (1) EP3897591A1 (fr)
JP (1) JP2022514056A (fr)
KR (1) KR20210105388A (fr)
CN (1) CN113453671A (fr)
AU (1) AU2019407159A1 (fr)
BR (1) BR112021011699A2 (fr)
CA (1) CA3123510A1 (fr)
CL (1) CL2021001623A1 (fr)
IL (1) IL283937A (fr)
MX (1) MX2021007477A (fr)
TW (1) TW202038964A (fr)
WO (1) WO2020128878A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
US20240000789A1 (en) * 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20180250302A1 (en) * 2015-08-28 2018-09-06 Giordano Caponigro Combination of ribociclib and dabrafenib for treating or preventing cancer
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法

Also Published As

Publication number Publication date
CL2021001623A1 (es) 2022-02-11
IL283937A (en) 2021-07-29
EP3897591A1 (fr) 2021-10-27
AU2019407159A1 (en) 2021-07-15
TW202038964A (zh) 2020-11-01
JP2022514056A (ja) 2022-02-09
KR20210105388A (ko) 2021-08-26
WO2020128878A1 (fr) 2020-06-25
CA3123510A1 (fr) 2020-06-25
MX2021007477A (es) 2021-08-05
BR112021011699A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
CN110494166B (zh) 组合疗法
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
US20200237711A1 (en) Compositions for Treating and/or Preventing Cancer
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
US20230088701A1 (en) Combination therapies for treatment of breast cancer
KR20140022053A (ko) Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
CN115551509A (zh) 包含craf抑制剂的治疗组合
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
KR102686264B1 (ko) 소세포폐암 치료용 치아우라닙
JP7361779B2 (ja) がんに治療的処置をするためのｃ－１９ステロイドの組み合わせ
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
KR20220124739A (ko) 암의 치료를 위한 병용 요법
CN110494137B (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination